Dr. Marwan Mohammad Al-Haddad, MD

Dr. Al-Haddad practices at Slocum-Dickson Medical Group - New Hartford in New Hartford, New York.

Dr. Al-Haddad's NPI, 1518301712, was assigned on April 18, 2013. Dr. Al-Haddad holds New York license 295454.

Dr. Al-Haddad's primary practice is Slocum-Dickson Medical Group - New Hartford, at 1729 Burrstone Rd, New Hartford, NY 13413. The practice phone is (315) 798-1465.

Dr. Al-Haddad's primary practice is Slocum-Dickson Medical Group - New Hartford in New Hartford, New York. The medical group on file is Slocum-Dickson Medical Group. Dmand AI also links Dr. Al-Haddad to 1 more group practice or clinic, named with a free account. Dr. Al-Haddad's employer is on file too: a clinical lab.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Al-Haddad practices, 2 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Al-Haddad's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Al-Haddad is licensed in New York.

CMS data shows 5,281 Medicare services from Dr. Al-Haddad across 18 procedure codes in 2024, for 1,196 Medicare patients. Medicare paid $184,133 for them. Every service was in an office.

CMS counts 1,196 Medicare patients who saw Dr. Al-Haddad in 2024. The largest group is 75 to 84, with 487 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 0.93, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Al-Haddad's median patient age at 70, with 54% women.

In 2024, Dr. Al-Haddad wrote 1,475 Medicare Part D claims for 610 patients. 89% of them were for generic drugs. CMS names the drug for 1,242 of them, across 30 drugs with 11 or more claims each, at $358,836 in total drug cost. In 2023, CMS named 1,600 claims across 37 drugs.

Dr. Al-Haddad accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 1,434 procedures of removal of skin lesions by Dr. Al-Haddad, more than 96% of the clinicians it reports for that procedure.

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links Dr. Al-Haddad to 1 clinical trial. Conditions studied include Cellulite and Skin Manifestations. Open Payments lists research payments to Dr. Al-Haddad that name 1 trial.

CMS Open Payments shows 442 general payments to Dr. Al-Haddad from 37 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 82% of the total. Abbvie Inc. paid the most, $2,369. It also lists 7 research payments totaling $1,546 in 2018, naming 1 clinical trial.